[Federal Register Volume 66, Number 141 (Monday, July 23, 2001)]
[Notices]
[Pages 38282-38283]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 01-18285]


-----------------------------------------------------------------------

DEPARTMENT OF HEALTH AND HUMAN SERVICES

Centers for Disease Control and Prevention

[Program Announcement 01146]


Expansion of HIV/AIDS Prevention Activities in the Republic of 
Kenya; Notice of Availability of Funds

A. Purpose

    The Centers for Disease Control and Prevention (CDC) announces the 
availability of fiscal year (FY) 2001 funds for a cooperative agreement 
program for Global AIDS Program.
    The purpose of the program is to provide assistance in developing a 
disease Surveillance program for the control of HIV/AIDS in the country 
of Kenya, and to support activities to reduce the burden of 
tuberculosis.

B. Eligible Applicants

Single Source

    Assistance will be provided only to the Ministry of Health (MOH) of 
the Country of Kenya. No other applications are solicited.
    This announcement is restricted to the MOH or subservient agencies 
of the government of Kenya as they are the only legislated entity with 
the authority and responsibility to collect such data for the purpose 
of the control of HIV/AIDS, communicable disease and the maintenance of 
public health.

A. Availability of Funds

    Funds are available under this announcement to fund two specific 
activities with funding amounts identified for each activity. These 
activities are:
    1. HIV/AIDS Surveillance Activities including:
    (a) Monitoring of Blood Safety
    (b) Overall monitoring of HIV VCT and Mother to Child Transmission 
within Kenya--$500,000
    2. Tuberculosis Surveillance and Control as it relates to HIV/
AIDS--$1 million
    Each component or program activity for which funds are requested 
should be specifically identified with Goals, Plan, Objectives, 
Activities, Method of Evaluation and budget provided. A summary budget 
by line item should be provided.
    It is expected that the awards will begin on or about September 30, 
2001 and will be made for a 12-month budget period within a project 
period of up to five (5) years. Funding estimates may change.
    Continuation awards within an approved project period will be made 
on the basis of satisfactory progress as evidenced by required reports 
and the availability of funds.

Use of Funds

Antiretroviral Drugs
    Funds received from this announcement will not be used for the 
purchase of antiretroviral drugs for treatment of established HIV 
infection (with the exception nevirapine in PMTCT cases and with prior 
written approval), occupational exposures, and non-occupational 
exposures and will not be used for the purchase of machines and 
reagents to conduct the necessary laboratory monitoring for patient 
care.
    Applicants may contract with other organizations under these 
cooperative agreements, however, applicants must perform a substantial 
portion of the activities including program management and operations 
and delivery of prevention services for which funds are requested.
    The costs that are generally allowable in grants to domestic 
organizations are likewise allowable to foreign institutions and 
international organizations, with the following exceptions:
    Indirect Costs: With the exception of the American University, 
Beirut, the Gorgas Memorial Institute, and the World Health 
Organization, indirect costs will not be paid (either directly or 
through a sub-award) to organizations located outside the territorial 
limits of the United States or to international organizations 
regardless of their location.
    All requests for funds, including the budget contained in the 
application, shall be stated in U.S. dollars. Once an award is made, 
the Department of Health and Human Services (DHHS) will not compensate 
foreign grantees for currency exchange fluctuations through the 
issuance of supplemental awards.
Needle Exchange
    No funds appropriated under this Act shall be used to carry out any 
program of distributing sterile needles or syringes for the hypodermic 
injection of any illegal drug.

[[Page 38283]]

D. Where to Obtain Additional Information

    This and other CDC announcements can be found on the CDC home page 
Internet address--http://www.cdc.gov. Click on ``Funding'' then 
``Grants and Cooperative Agreements.''
    To obtain business management technical assistance, contact: 
Dorimar Rosado, Grants Management Specialist, Grants Management Branch, 
Procurement and Grants Office, Centers for Disease Control and 
Prevention, 2920 Brandywine Road, Room 3000, Atlanta, GA 30341-4146, 
Telephone number (770) 488-2782, E-mail address: [email protected].
    For program technical assistance, contact: Lawrence H. Marum, M.D., 
FAAP, MPH, CDC LIFE Initiative P.O. Box 30137, Nairobi, National AIDS/
ASTD Control Programme (NASCOP), P.O. Box 30137, Nairobi, Kenya.
    US Mail: Unit 64112, APO, AE 09831-4112, Telephone number: +254-72-
721-781 or +254-2-729-549, Fax: +254-2-714-745, E-mail: 
[email protected].

    Dated: July 17, 2001.
John L. Williams,
Director, Procurement and Grants Office, Centers for Disease Control 
and Prevention (CDC).
[FR Doc. 01-18285 Filed 7-20-01; 8:45 am]
BILLING CODE 4163-18-P